Half-year Report
RNS Number : 5334I
Adams PLC
27 November 2018
Adams plc
("Adams" or the "Company")
Interim Results for the Six Months ended 30 September 2018
Adams (AIM: ADA) delivered a profit after tax of £517,000 in the six months ended 30 September 2018 compared to a loss of £51,000 in the half year to 30 September 2017. The increase in profitability is principally due to investment returns being higher by £572,000.
The presentational currency of Adams was changed from Euros to Pounds Sterling during the year to 31 March 2018. In accordance with accounting standards, the comparative financial information for the half year ended 30 September 2017 as previously reported in Euros, has been presented in Pounds Sterling using the procedures outlined in note 4.2 to the condensed financial statements.
During the six months ended 30 September 2018, the Company remained almost fully invested and did not make any new investments or make any investment disposal realisations.
Adams held 6 investments at 30 September 2018, of which 3 were listed and 3 were un-listed, and for which the total investment carrying value was £2.62 million (31 March 2018: £2.08 million, represented by 3 listed and 3 un-listed investment holdings).
The Company held cash balances of £30,000 at 30 September 2018, compared to cash balances of £52,000 at the previous 31 March 2018 year end. Net assets attributable to shareholders of Adams at 30 September 2018 were £2.63 million (equivalent to 3.18 pence per share) versus £2.11 million (equivalent to 2.55 pence per share) at 31 March 2018.
Business model and investing policy
Adams is an investing company with an investing policy under which the Board is seeking to acquire interests in special situation investment opportunities that have an element of distress, dislocation, dysfunction or other special situation attributes and that the Board perceives to be undervalued. The principal focus is in the small to middle-market capitalisation sectors in the UK or Europe, but the directors will also consider possible special situation opportunities anywhere in the world if they believe there is an opportunity to generate added value for shareholders.
Investment Portfolio
The listed investments held by the Company at 30 September 2018 comprise Petrofac Limited, Eland Oil & Gas Plc and Communisis Plc. In addition, the Company held shares and loan notes in unquoted Sherwood Holdings Limited (which owns Source Bioscience Ltd as its principal subsidiary asset) and unquoted shares in both Abaco Capital Plc and Oxford Pharmascience Limited.
Petrofac is a multinational service provider to the oil and gas production and processing industry. The company designs, builds, operates and maintains oil and gas facilities with a focus on delivering first class project execution, cost control and effective risk management. Petrofac has a 36-year track record and has grown significantly to become a constituent of the FTSE 250 Index. The company has 31 offices and approximately 13,500 staff worldwide, comprising more than 80 nationalities.
Eland is an independent oil and gas company with principal interests in the prolific Niger Delta. During 2018 to date, average gross production increased to around 30,000 barrels of oil per day and is expected to continue to increase further in the near-term.
Communisis is a leading provider of outsourced digital asset management and personalised customer communication services. On 23 October 2018, Bidco Ltd, a wholly-owned indirect subsidiary of OSG Group Holdings Inc., made a recommended 71 pence per share cash offer for the entire share capital of Communisis. It is proposed that the cash acquisition be implemented by means of a court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act, which requires the approval of Communisis shareholders at a court meeting and general meeting and the sanction of the court. If approved, the acquisition is expected to complete in December 2018 and would generate cash proceeds of £143,000 for Adams on disposal of its investment holding in Communisis.
Abaco Capital (formerly Oxford Pharmascience Plc) underwent a demerger of its Oxford Pharmascience Limited business in December 2017 and cancelled its AIM listing in May 2018. The company subsequently undertook a members' voluntary liquidation and a distribution of funds back to shareholders under which Adams received a £30,000 payment in October 2018. As a result and subsequent to Adams's 30 September 2018 half year end, the Company no longer has an investment holding in Abaco Capital.
Oxford Pharmascience (as demerged from Abaco Capital) is a drug development company that re-develops approved drugs to make them better, safer and easier to take and it has a current focus to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins. Subsequent to Adams's 30 September 2018 half year end, the Company sold its small investment holding in Oxford Pharmascience for £3,000.
Source Bioscience is an international provider of state of the art laboratory services and products and has an expertise in clinical diagnostics, genomics, proteomics, drug discovery & development research and analytical testing services.
Outlook
There is continued reason for investment caution in the near term, given the many threats to a sustained global recovery, including a trade war between the US and China, rising US interest rates, the tightening of global monetary conditions and ongoing Brexit uncertainties.
Weak equity markets in the current December quarter period to date have adversely impacted the value of our investment holdings and reversed some of the investment gains reported in the six months ended 30 September 2018. We remain committed, however, to delivering additional value for our shareholders and will continue to maintain a rigorous and highly selective investment approach with a view to exploiting opportunities as they emerge. We are confident that this approach will enable us to build considerable value for shareholders going forward.
Michael Bretherton
Chairman
27 November 2018
Enquiries:
| Adams plc | |
| Mike Bretherton | Tel: +44 1534 719 761 |
| Nomad | |
| Cairn Financial Advisers LLP | |
| Sandy Jamieson, James Caithie | Tel: +44 207 213 0880 |
| Broker | |
| Peterhouse Corporate Finance Limited | |
| Lucy Williams, Duncan Vasey | Tel: +44 207 469 0930 |
| 6 months ended 30 Sep 2018 | Year ended 31 Mar 2018 | 6 months ended 30 Sep 2017 | ||
| Note | (Unaudited) | (Audited) | (Unaudited) | |
| £'000 | £'000 | £'000 | ||
| Gain on investments | 5 | 541 | 280 | 13 |
| Dividend income | 57 | 45 | 13 | |
| Investment return | 598 | 325 | 26 | |
| Expenses | ||||
| Administrative expenses | (86) | (155) | (82) | |
| Operating profit/(loss) | 512 | 170 | (56) | |
| Interest income | 5 | 10 | 5 | |
| Profit/(loss) on ordinary activities before taxation | 517 | 180 | (51) | |
| Tax on profit/(loss) on ordinary activities | - | - | - | |
| Profit/(loss) for the period | 517 | 180 | (51) | |
| Total comprehensive income/(loss) for the period | 517 | 180 | (51) | |
| Earnings/(loss) per ordinary share | ||||
| Basic and diluted | 10 | 0.63p | 0.25p | (0.08)p |
| As at 30 Sep 2018 | As at 31 Mar 2018 | As at 30 Sep 2017 | |||
| (Unaudited) | (Audited) | (Unaudited) | |||
| Note | £'000 | £'000 | £'000 | ||
| Assets | |||||
| Non-current assets | |||||
| Investments | 6 | 2,622 | 2,076 | 1,822 | |
| Current assets | |||||
| Trade and other receivables | 7 | 6 | 2 | 1 | |
| Cash and cash equivalents | 30 | 52 | 78 | ||
| Current assets | 36 | 54 | 79 | ||
| Total assets | 2,658 | 2,130 | 1,901 | ||
| Liabilities | |||||
| Current liabilities | |||||
| Trade and other payables | 8 | (32) | (21) | (23) | |
| Total liabilities | (32) | (21) | (23) | ||
| Net current assets | 4 | 33 | 56 | ||
| Net assets | 2,626 | 2,109 | 1,878 | ||
| Equity | |||||
| Called up share capital | 9 | 826 | 1,001 | 1,001 | |
| Share premium | 9 | - | 1,401 | 1,401 | |
| Accumulated gains/(losses) | 1,800 | (49) | (280) | ||
| Foreign currency translation reserve | - | (244) | (244) | ||
| Total shareholder equity | 2,626 | 2,109 | 1,878 | ||
| Share Capital | Share Premium | Foreign currency translation reserve | Accumulated gains/(losses) | Total | |
| £'000 | £'000 | £'000 | £'000 | £'000 | |
| At 31 March 2017 (audited) | 636 | 783 | (244) | (229) | 946 |
| Issue of shares | 365 | 618 | - | - | 983 |
| Total comprehensive loss for period | - | - | - | (51) | (51) |
| At 30 September 2017 (unaudited) | 1,001 | 1,401 | (244) | (280) | 1,878 |
| Total comprehensive gain for period | - | - | - | 231 | 231 |
| At 31 March 2018 (audited) | 1,001 | 1,401 | (244) | (49) | 2,109 |
| Total comprehensive gain for period | - | - | - | 517 | 517 |
| Redenomination of share capital | (175) | 175 | - | - | - |
| Elimination of foreign currency reserve | - | (244) | 244 | - | - |
| Reclassification of share premium | - | (1,332) | - | 1,332 | - |
| At 30 September 2018 (unaudited) | 826 | - | - | 1,800 | 2,626 |
| 6 months ended 30 Sep 2018 | Year ended 31 Mar 2018 | 6 months ended 30 Sep 2017 | |
| (Unaudited) | (Audited) | (Unaudited) | |
| £'000 | £'000 | £'000 | |
| Profit/(loss) for the period | 517 | 180 | (51) |
| Unrealised gain on revaluation of investments | (541) | (237) | (14) |
| Realised (gain)/loss on disposal of investments | - | (43) | 1 |
| (Increase)/decrease in trade and other receivables | (4) | - | 1 |
| Increase/(decrease) in trade and other payables | 11 | (5) | (3) |
| Net cash outflows from operating activities | (17) | (105) | (66) |
| Cash flows from investing activities | |||
| Proceeds from sales of investments | - | 730 | 72 |
| Purchase of investments | (5) | (1,591) | (946) |
| Net cash used in investing activities | (5) | (861) | (874) |
| Cash flows from financing activities | |||
| Issue of ordinary share capital | - | 983 | 983 |
| Net cash generated from financing activities | - | 983 | 983 |
| Net (decrease)/increase in cash and cash equivalents | (22) | 17 | 43 |
| Cash and cash equivalents at beginning of period | 52 | 35 | 35 |
| Cash and cash equivalents at end of period | 30 | 52 | 78 |
| 6 months ended 30 Sep 2018 | Year ended 31 Mar 2018 | 6 months ended 30 Sep 2017 | |
| £'000 | £'000 | £'000 | |
| Unrealised gain on investments | 541 | 237 | 14 |
| Realised gain/(loss) on investments | - | 43 | (1) |
| Total gain on investments | 541 | 280 | 13 |
| Quoted Equity Shares | Unquoted Equity Shares | Unquoted Loan Notes | Total | |
| £'000 | £'000 | £'000 | £'000 | |
| Fair value at 31 March 2017 | 837 | 5 | 93 | 935 |
| Additions at cost | 941 | - | 5 | 946 |
| Disposals | (73) | - | - | (73) |
| Unrealised revaluation gains | 14 | - | - | 14 |
| Fair value at 30 September 2017 | 1,719 | 5 | 98 | 1,822 |
| Additions at cost | 640 | - | 5 | 645 |
| Disposals | (614) | - | - | (614) |
| Unrealised revaluation gains | 223 | - | - | 223 |
| Fair value at 31 March 2018 | 1,968 | 5 | 103 | 2,076 |
| Additions at cost | - | - | 5 | 5 |
| Unrealised revaluation gains | 541 | - | - | 541 |
| Fair value at 30 September 2018 | 2,509 | 5 | 108 | 2,622 |
| As at 30 Sep 2018 | As at 31 Mar 2018 | As at 30 Sep 2017 | |
| £'000 | £'000 | £'000 | |
| Prepayments | 6 | 2 | 1 |
| 6 | 2 | 1 |
| As at 30 Sep 2018 | As at 31 Mar 2018 | As at 30 Sep 2017 | |
| £'000 | £'000 | £'000 | |
| Trade payables | 13 | 8 | 13 |
| Accruals and other creditors | 19 | 13 | 10 |
| 32 | 21 | 23 |
| Ordinary shares | Number of shares issued and fully paid up | Share capital £'000 | Share premium £'000 |
| At 1 April 2017 | 41,276,616 | 636 | 783 |
| Issue of shares | 41,276,616 | 365 | 618 |
| At 30 September 2017 | 82,553,232 | 1,001 | 1,401 |
| Issue of shares | - | - | - |
| At 31 March 2018 | 82,553,232 | 1,001 | 1,401 |
| Redenomination of share capital | - | (175) | 175 |
| Elimination of foreign currency reserve | - | - | (244) |
| Reclassification of share premium | - | - | (1,332) |
| At 30 September 2018 | 82,553,232 | 826 | - |
| 6 months ended 30 Sep 2018 | Year ended 31 Mar 2018 | 6 months ended 30 Sep 2017 | |
| Profit/(loss) after tax attributable to equity holders of the Company (£'000) | 517 | 180 | (51) |
| Weighted average number of ordinary shares | 82,553,232 | 72,481,267 | 62,478,812 |
| Basic and diluted earnings/(loss) per share | 0.63p | 0.25p | (0.08)p |